RECURSION PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $74.7M | $58.8M | $44.6M | $39.8M | $10.2M |
| Operating income | -$648.1M | -$479.0M | -$350.1M | -$245.7M | -$182.8M |
| Operating expenses | — | — | — | — | $193.0M |
| Cost of revenue | $71.0M | $45.2M | $42.6M | $48.3M | $0 |
| Cash from operations | -$371.8M | -$359.2M | -$287.8M | -$83.5M | -$158.6M |
| Capital expenditure | $6.5M | $13.7M | $12.0M | $37.1M | $39.8M |
| Free cash flow | -$378.3M | -$372.9M | -$299.7M | -$120.6M | -$198.4M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $1.5B | $1.4B | $653.7M | $701.3M | $610.3M |
| Total liabilities | $343.3M | $413.8M | $190.3M | $215.5M | $67.4M |
Shares outstanding 529.9M · Free float 93.1%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.